If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.
Following recent publication of the article ‘Treatable traits in the NOVELTY study’ in Respirology, findings from this important study have been used to inform part of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 report.
The GOLD report is a key evidence-based strategy document for COPD diagnosis, management, and prevention. The 2023 report expands on the treatable traits strategy and refers to results from the article that show how treatable traits can co-exist in the same patient and can be shared between patients with asthma and COPD. The importance of two key treatable traits (persistent dyspnoea and exacerbations) is highlighted in the GOLD follow-up algorithm of pharmacological treatment; the NOVELTY article is cited to support the point that there are many more traits and risk factors that require attention and treatment if present. The GOLD 2023 report proposes a tailored approach to treatment based on the presence of treatable traits, highlighting the importance of treatable traits in moving towards a precision medicine approach whereby patients are managed based on clinical presentation rather than their diagnostic label.
The GOLD 2023 report is available here.
The NOVELTY treatable traits article is available here.
The previous news item on the NOVELTY treatable traits article is available here.
You are now leaving: http://aznoveltyproject.com/
By following this link you will be leaving the NOVELTY study website.
Please note that AstraZeneca does not take responsibility for the content displayed on other websites.